A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2002
12/10/2002	CA2202924C Use of at least one lipoxygenase inhibitor and at least one cyclo-oxygenase inhibitor to alter the growth of hair
12/08/2002	WO2003000892A1 Gene encoding b protein
12/08/2002	CA2398093A1 Gene encoding protein b
12/08/2002	CA2392486A1 Pharmaceutical dosage form bearing pregnancy-friendly indicia
12/08/2002	CA2386262A1 Method for nasal application of a medicinal substance
12/05/2002	WO2002097395A2 P-cadherin as a target for anti-cancer therapy
12/05/2002	WO2002097114A2 Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
12/05/2002	WO2002097094A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis
12/05/2002	WO2002097079A2 Gene encoding molecular motor protein and diagnosis method for the disease related to the gene
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097053A2 Small molecule antagonists of bcl2 family proteins
12/05/2002	WO2002097046A2 B7 related protein-2 molecules and uses thereof
12/05/2002	WO2002097045A2 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore
12/05/2002	WO2002097043A2 Wnv core protein/capsid interacting protein and uses of the same
12/05/2002	WO2002097035A2 Secreted proteins
12/05/2002	WO2002097033A2 Antibodies that immunospecifically bind to trail receptors
12/05/2002	WO2002097032A2 Proteins associated with cell growth, differentiation, and death
12/05/2002	WO2002096951A1 Molecules for disease detection and treatment
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096927A2 Ribozyme based treatment of female reproductive diseases
12/05/2002	WO2002096926A1 Modulators of pharmacological agents
12/05/2002	WO2002096909A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
12/05/2002	WO2002096903A2 Chemical derivatives and the use thereof as an anti-telomerase agent
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096516A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
12/05/2002	WO2002096463A1 A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
12/05/2002	WO2002096462A1 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
12/05/2002	WO2002096458A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	WO2002096456A1 Use of il-18 inhibitors for treating or preventing cns injuries
12/05/2002	WO2002096438A1 Synergistic antibiotic compositions
12/05/2002	WO2002096436A1 The use of a compound with a negatively charged domain of radicals for the treatment of restenosis
12/05/2002	WO2002096435A2 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
12/05/2002	WO2002096433A1 Methods for treating delirium using glucocorticoid receptor-specific antagonists
12/05/2002	WO2002096432A2 Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same
12/05/2002	WO2002096428A1 Pharmaceutical combinations
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096423A2 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
12/05/2002	WO2002096422A2 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
12/05/2002	WO2002096414A1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy
12/05/2002	WO2002096407A1 Liquid drug preparations
12/05/2002	WO2002096404A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
12/05/2002	WO2002096403A1 Composition containing 2-aminophenylacetic acid
12/05/2002	WO2002096398A2 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus
12/05/2002	WO2002096393A1 Anorexic composition comprising calcium acetate
12/05/2002	WO2002096374A2 Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096357A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096354A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
12/05/2002	WO2002096353A2 Polymer controlled induced viscosity fiber system and uses thereof
12/05/2002	WO2002096348A2 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
12/05/2002	WO2002096223A1 Dual viscosity fiber system and uses thereof
12/05/2002	WO2002096219A2 Acid controlled viscosity fiber system and uses thereof
12/05/2002	WO2002096216A1 A method of improving the growth performance of an animal
12/05/2002	WO2002096202A1 Antibacterial composition containing an organic acid and copper salt
12/05/2002	WO2002081415A3 Method for inhibiting metap2
12/05/2002	WO2002078720A3 Antibiotics from bacteria isolated from amphibian skin
12/05/2002	WO2002078633A8 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
12/05/2002	WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002063954A3 USE OF β-LACTAMASE INHIBITORS AS NEUROPROTECTANTS
12/05/2002	WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
12/05/2002	WO2002059150A3 Materials and methods relating to protein aggregation in neurodegenerative disease
12/05/2002	WO2002056902A3 Ccr5 antagonist and dp-178 polypeptide for treating viral infections
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2002047728A3 Treatment of posterior capsule opacification
12/05/2002	WO2002042321A3 Mixed fibrils
12/05/2002	WO2002038732A3 Human testis specific serine/threonine kinase
12/05/2002	WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same
12/05/2002	WO2002020766A3 G-csf analog compositions and methods
12/05/2002	WO2002006453A3 Regulation of human desc1-like serine protease
12/05/2002	WO2002000715A3 Mammal 2p domain mechano-sensitive k+ channel, cloning and applications thereof
12/05/2002	WO2001097608A3 Cyk-4 polypeptides, dna molecules encoding them and their use in screening methods
12/05/2002	WO2001093909A3 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis
12/05/2002	WO2001079448A3 Trp8, a transient receptor potential channel expressed in taste receptor cells
12/05/2002	WO2001064949B1 Diagnostics and therapeutics for glaucoma
12/05/2002	WO2001060397A9 Uses of agonists and antagonists to modulate activity of tnf-related molecules
12/05/2002	WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
12/05/2002	US20020183808 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant
12/05/2002	US20020183687 Adhesion prevention and an endoscopic insufflation system therefor
12/05/2002	US20020183507 Novel human GABA receptor proteins and polynucleotides encoding the same
12/05/2002	US20020183399 Method and compositions for treating rosacea
12/05/2002	US20020183398 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
12/05/2002	US20020183396 Local anesthetic methods and kits
12/05/2002	US20020183390 Administration of a D-serine transport inhibitor (serine dodecylamide, alanine dodecylamide or glycyldodecylamide) sufficient to enhance (N-methyl-D-aspartate) receptor mediated neurotransmission in vivo for psychological disorder
12/05/2002	US20020183387 Topically applying to the affected area in the nail a lower alcohol and a lower carboxylic acid to treat the bacterial or fungal infection
12/05/2002	US20020183385 Administering a therapeutically effective amount of arsenic compounds to a mammal for treating solid tumor
12/05/2002	US20020183379 Kits for determining risk of Alzheimer's disease
12/05/2002	US20020183369 For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis
12/05/2002	US20020183368 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
12/05/2002	US20020183367 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
12/05/2002	US20020183357 Therapy of stress urinary incontinence by administering a compound that is an alpha 1A adrenoceptor agonist and an alpha 1B antagonist
12/05/2002	US20020183356 Local anesthetic methods and kits
12/05/2002	US20020183345 Administering to a drug naive human patient in need of treatment, as first line therapy, a low dose of a combination of metformin and glyburide
12/05/2002	US20020183318 Novel derivatives of flavones, xanthones and coumarins
12/05/2002	US20020183312 Combination of cyamemazine and an atypical neuroleptic
12/05/2002	US20020183306 Combination treatment for sleep disorders including sleep apnea
12/05/2002	US20020183305 For therapy of hyperlipidemic conditions such as are associated with atherosclerosis, hypercholesterolemia and other vascular conditions in mammals
12/05/2002	US20020183304 For prophylaxis or reducing neuronal damage in patients suffering from or susceptible to disease states characterized by loss of neuronal cells or loss of neuronal cell function

1 ... 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 ... 1151